DK1056725T3 - Inhibering af raf-kinase ved hjælp af aryl- og heteroaryl-substituerede heterocykliske urinstoffer - Google Patents

Inhibering af raf-kinase ved hjælp af aryl- og heteroaryl-substituerede heterocykliske urinstoffer

Info

Publication number: DK1056725T3
Authority: DK; Denmark
Prior art keywords: heteroaryl; inhibition; aryl; raf kinase; substituted heterocyclic
Prior art date: 1997-12-22

Application number

DK98963810T

Other languages

Danish (da)

English (en)

Inventor

Jacques Dumas

Uday Khire

Bernd Riedl

William J Scott

Roger A Smith

Jill E Wood

Holia Hatoum-Mokdad

Jeffrey Johnson

Aniko Redman

Robert Sibley

Timothy Bruno Lowinger

Original Assignee

Bayer Pharmaceuticals Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-22

Filing date

1998-12-22

Publication date

2006-10-02

1998-12-22 Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp

2006-10-02 Application granted granted Critical

2006-10-02 Publication of DK1056725T3 publication Critical patent/DK1056725T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

DK98963810T 1997-12-22 1998-12-22 Inhibering af raf-kinase ved hjælp af aryl- og heteroaryl-substituerede heterocykliske urinstoffer DK1056725T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US99618197A	1997-12-22	1997-12-22

Publications (1)

Publication Number	Publication Date
DK1056725T3 true DK1056725T3 (da)	2006-10-02

Family

ID=25542594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98963810T DK1056725T3 (da)	1997-12-22	1998-12-22	Inhibering af raf-kinase ved hjælp af aryl- og heteroaryl-substituerede heterocykliske urinstoffer

Country Status (29)

Country	Link
EP (1)	EP1056725B1 (ko)
JP (1)	JP4395823B2 (ko)
KR (1)	KR100622138B1 (ko)
CN (1)	CN1117081C (ko)
AT (1)	ATE328873T1 (ko)
AU (1)	AU765412B2 (ko)
BG (1)	BG65207B1 (ko)
BR (1)	BR9814361A (ko)
CA (1)	CA2315713C (ko)
CU (1)	CU23127A3 (ko)
CY (1)	CY1105395T1 (ko)
CZ (1)	CZ299836B6 (ko)
DE (2)	DE1056725T1 (ko)
DK (1)	DK1056725T3 (ko)
ES (1)	ES2155045T3 (ko)
GR (1)	GR20010300010T1 (ko)
HK (1)	HK1029989A1 (ko)
HU (1)	HUP0004426A3 (ko)
ID (1)	ID26328A (ko)
IL (2)	IL136773A0 (ko)
NO (1)	NO319209B1 (ko)
NZ (1)	NZ505845A (ko)
PL (1)	PL341356A1 (ko)
PT (1)	PT1056725E (ko)
RU (1)	RU2265597C2 (ko)
SK (1)	SK285371B6 (ko)
TR (3)	TR200100918T2 (ko)
UA (1)	UA67763C2 (ko)
WO (1)	WO1999032455A1 (ko)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1473292A1 (en) *	1997-11-03	2004-11-03	Boehringer Ingelheim Pharmaceuticals, Inc.	Aromatic heterocyclic compounds as anti-inflammatory agents
IL136767A0 (en) *	1997-12-22	2001-06-14	Bayer Ag	Inhibition of raf kinase using substituted heterocyclic ureas
AU2006201959B2 (en) *	1997-12-22	2008-09-04	Bayer Healthcare Llc	Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
US7517880B2 (en)	1997-12-22	2009-04-14	Bayer Pharmaceuticals Corporation	Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en)	1997-12-22	2008-02-12	Bayer Pharmaceuticals Corporation	Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
WO1999032110A1 (en) *	1997-12-22	1999-07-01	Bayer Corporation	INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
ATE529109T1 (de) *	1997-12-22	2011-11-15	Bayer Healthcare Llc	Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
JP2002534468A (ja)	1999-01-13	2002-10-15	バイエルコーポレイション	ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US7928239B2 (en) *	1999-01-13	2011-04-19	Bayer Healthcare Llc	Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en)	1999-01-13	2008-04-01	Bayer Pharmaceuticals Corporation	ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (en)	1999-01-13	2006-03-22	Bayer Pharmaceuticals Corp.	-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UA73492C2 (en)	1999-01-19	2005-08-15		Aromatic heterocyclic compounds as antiinflammatory agents
EP1157026A1 (en)	1999-02-22	2001-11-28	Boehringer Ingelheim Pharmaceuticals Inc.	Polycyclo heterocyclic derivatives as antiinflammatory agents
WO2000051998A1 (en)	1999-03-02	2000-09-08	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as reversible inhibitors of cathepsin s
EE04799B1 (et)	1999-03-12	2007-04-16	Boehringer Ingelheim Pharmaceuticals, Inc.	Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
WO2000055152A1 (en)	1999-03-12	2000-09-21	Boehringer Ingelheim Pharmaceuticals, Inc.	Aromatic heterocyclic compounds as anti-inflammatory agents
DE60024830T2 (de)	1999-07-09	2006-06-14	Boehringer Ingelheim Pharma	Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
BR0013143A (pt) *	1999-08-12	2002-06-11	Pharmacia Italia Spa	Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
US6420364B1 (en)	1999-09-13	2002-07-16	Boehringer Ingelheim Pharmaceuticals, Inc.	Compound useful as reversible inhibitors of cysteine proteases
TR200201364T2 (tr)	1999-11-22	2002-10-21	Smithkline Beecham P. L. C.	Yeni bileşikler.
US6525046B1 (en)	2000-01-18	2003-02-25	Boehringer Ingelheim Pharmaceuticals, Inc.	Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en)	2000-02-16	2003-08-19	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as anti-inflammatory agents
DK1320531T3 (da) *	2000-08-10	2011-01-03	Pfizer Italia Srl	Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
US6645990B2 (en)	2000-08-15	2003-11-11	Amgen Inc.	Thiazolyl urea compounds and methods of uses
US7238813B2 (en)	2000-11-29	2007-07-03	Smithkline Beecham Corporation	Chemical compounds
US7235576B1 (en)	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en)	2001-04-20	2008-05-13	Bayer Pharmaceuticals Corporation	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2004530690A (ja)	2001-05-16	2004-10-07	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	抗炎症性薬剤として有用なジアリールウレア誘導体
GB0112348D0 (en)	2001-05-19	2001-07-11	Smithkline Beecham Plc	Compounds
MXPA03010724A (es)	2001-05-25	2004-03-02	Boehringer Ingelheim Pharma	Compuestos de carbamato y oxamida como inhibidores de la produccion de citocina.
EP1709965A3 (en) *	2001-07-11	2006-12-27	Boehringer Ingelheim Pharmaceuticals, Inc.	Methods of treating cytokine mediate diseases
WO2003022838A1 (en) *	2001-09-05	2003-03-20	Smithkline Beecham Plc	Pyridine substituted furan derivatives as raf kinase inhibitors
RU2316326C2 (ru) *	2001-12-03	2008-02-10	Байер Фамэсьютиклс Копэрейшн	Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины
EP2324825A1 (en)	2002-02-11	2011-05-25	Bayer Healthcare LLC	Aryl ureas with angiogenesis inhibiting activity
AU2003209118A1 (en)	2002-02-11	2003-09-04	Bayer Pharmaceuticals Corporation	Aryl ureas as kinase inhibitors
US10653684B2 (en)	2002-02-11	2020-05-19	Bayer Healthcare Llc	Aryl ureas with angiogenisis inhibiting activity
US20040023961A1 (en) *	2002-02-11	2004-02-05	Bayer Corporation	Aryl ureas with raf kinase and angiogenisis inhibiting activity
WO2003072569A1 (en)	2002-02-25	2003-09-04	Boehringer Ingelheim Pharmaceuticals, Inc.	1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
BR0312913A (pt) *	2002-07-25	2005-07-12	Pharmacia Italia Spa	Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo
US7202257B2 (en)	2003-12-24	2007-04-10	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
US7144911B2 (en)	2002-12-31	2006-12-05	Deciphera Pharmaceuticals Llc	Anti-inflammatory medicaments
UY28213A1 (es)	2003-02-28	2004-09-30	Bayer Pharmaceuticals Corp	Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1608639A2 (en)	2003-02-28	2005-12-28	Bayer Pharmaceuticals Corporation	Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
KR20060025141A (ko)	2003-05-15	2006-03-20	아르퀼 인코포레이티드	Ｐ38의 억제제 및 이를 사용하는 방법
JP4860474B2 (ja)	2003-05-20	2012-01-25	バイエル、ファーマシューテイカルズ、コーポレイション	Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素
JP4777887B2 (ja)	2003-07-23	2011-09-21	バイエル、ファーマシューテイカルズ、コーポレイション	病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
CA2545711A1 (en) *	2003-11-13	2005-06-02	Ambit Biosciences Corporation	Urea derivatives as kinase modulators
TW200530236A (en)	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
US20060211752A1 (en)	2004-03-16	2006-09-21	Kohn Leonard D	Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
DE602005025988D1 (de) *	2004-03-19	2011-03-03	Dipharma Francis Srl	Zwischenprodukte für die herstellung von pramipexol
EP1751139B1 (en)	2004-04-30	2011-07-27	Bayer HealthCare LLC	Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US7829560B2 (en)	2004-07-08	2010-11-09	Arqule, Inc.	1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
MY191349A (en) *	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP2258704A1 (en)	2004-10-19	2010-12-08	ArQule, Inc.	Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
GB0423554D0 (en) *	2004-10-22	2004-11-24	Cancer Rec Tech Ltd	Therapeutic compounds
WO2006071940A2 (en) *	2004-12-23	2006-07-06	Deciphera Pharmaceuticals, Llc	Enzyme modulators and treatments
GB0500435D0 (en) *	2005-01-10	2005-02-16	Novartis Ag	Organic compounds
CA2601955C (en)	2005-03-07	2012-07-10	Bayer Healthcare Ag	Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
JP5072595B2 (ja)	2005-08-05	2012-11-14	中外製薬株式会社	マルチキナーゼ阻害剤
DE102005037499A1 (de) *	2005-08-09	2007-02-15	Merck Patent Gmbh	Pyrazolderivate
CA2629468A1 (en) *	2005-11-15	2007-05-24	Bayer Pharmaceuticals Corporation	Pyrazolyl urea derivatives useful in the treatment of cancer
CA2634084C (en)	2005-12-21	2015-04-07	Roger Smith	Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
CA2652926A1 (en)	2006-05-26	2007-12-06	Bayer Healthcare Llc	Drug combinations with substituted diaryl ureas for the treatment of cancer
US7897762B2 (en)	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
US20100150863A1 (en)	2006-12-20	2010-06-17	Bayer Pharmaceuticals Corporation	Hydroxy methyl phenyl pyrazolyl urea compound useful in treatment of cancer
US7737149B2 (en) *	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8653091B2 (en)	2007-04-02	2014-02-18	Evotec Ag	Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof
MX2009011343A (es)	2007-04-20	2009-11-05	Deciphera Pharmaceuticals Llc	Inhibidores quinasa utiles para el tratamiento de enfermedades mieloproliferativas y otras enfermedades proliferativas.
PE20091561A1 (es)	2008-02-29	2009-10-30	Array Biopharma Inc	Compuestos inhibidores de raf y metodos para su uso
ES2400202T3 (es)	2008-02-29	2013-04-08	Array Biopharma, Inc.	Inhibidores de RAF de pirazol[3,4-B]piridina
BRPI0920707A2 (pt)	2008-10-02	2015-12-29	Respivert Ltd	compostos
GB0818033D0 (en)	2008-10-02	2008-11-05	Respivert Ltd	Novel compound
US8299073B2 (en)	2008-12-11	2012-10-30	Respivert Ltd.	P38 MAP kinase inhibitors
GB0905955D0 (en)	2009-04-06	2009-05-20	Respivert Ltd	Novel compounds
EP2556067B1 (en)	2010-04-08	2016-02-24	Respivert Limited	Pyrazolyl ureas as p38 map kinase inhibitors
WO2012008563A1 (ja)	2010-07-16	2012-01-19	協和発酵キリン株式会社	含窒素芳香族複素環誘導体
WO2012012404A1 (en)	2010-07-19	2012-01-26	Bayer Healthcare Llc	Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
PH12014500547A1 (en)	2011-10-03	2014-04-21	Respivert Ltd	1-pyrazolyl-3-(-4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors
EP2578582A1 (en)	2011-10-03	2013-04-10	Respivert Limited	1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR20140011780A (ko)	2012-07-19	2014-01-29	한미약품 주식회사	단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
GB201214750D0 (en)	2012-08-17	2012-10-03	Respivert Ltd	Compounds
GB201215357D0 (en)	2012-08-29	2012-10-10	Respivert Ltd	Compounds
EP2970190A1 (en)	2013-03-14	2016-01-20	Respivert Limited	Kinase inhibitors
WO2015066490A1 (en)	2013-10-31	2015-05-07	Ohio University	Prevention and treatment of non-alcoholic fatty liver disease
AU2015216705B2 (en)	2014-02-14	2019-03-28	Respivert Limited	Pyrazolyl-ureas as kinase inhibitors
US10023567B2 (en)	2014-07-18	2018-07-17	Ohio University	Imidazole and thiazole compositions for modifying biological signaling
WO2019152711A1 (en)	2018-01-31	2019-08-08	Diciphera Pharmaceuticals Llc.	Combination therapy for the treatment of gastrointestinal stromal tumors
WO2019152719A1 (en)	2018-01-31	2019-08-08	Deciphera Pharmaceuticals, Llc	Combination therapy for the treatment of mastocytosis
SI3762368T1 (sl)	2018-03-08	2022-06-30	Incyte Corporation	Aminopirazin diolne spojine kot zaviralci PI3K-y
CN108484587A (zh) *	2018-06-03	2018-09-04	刘思良	一种Raf激酶抑制剂及其在癌症治疗中的应用
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020010155A1 (en) *	2018-07-03	2020-01-09	Ifm Due, Inc.	Compounds and compositions for treating conditions associated with sting activity
CA3150433A1 (en)	2019-08-12	2021-02-18	Deciphera Pharmaceuticals, Llc	Ripretinib for treating gastrointestinal stromal tumors
WO2021030405A1 (en)	2019-08-12	2021-02-18	Deciphera Pharmaceuticals, Llc	Ripretinib for treating gastrointestinal stromal tumors
FI4084779T3 (fi)	2019-12-30	2024-12-16	Deciphera Pharmaceuticals Llc	1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
FI4084778T3 (fi)	2019-12-30	2023-12-18	Deciphera Pharmaceuticals Llc	Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5162360A (en) *	1991-06-24	1992-11-10	Warner-Lambert Company	2-heteroatom containing urea and thiourea ACAT inhibitors
GB9302275D0 (en) *	1993-02-05	1993-03-24	Smithkline Beecham Plc	Novel compounds
US5773459A (en) *	1995-06-07	1998-06-30	Sugen, Inc.	Urea- and thiourea-type compounds
GB9623833D0 (en) *	1996-11-16	1997-01-08	Zeneca Ltd	Chemical compound
CA2291065C (en) *	1997-05-23	2010-02-09	Bayer Corporation	Raf kinase inhibitors
AU1367599A (en) *	1997-11-03	1999-05-24	Boehringer Ingelheim Pharmaceuticals, Inc.	Aromatic heterocyclic compounds as anti-inflammatory agents
WO1999032110A1 (en) *	1997-12-22	1999-07-01	Bayer Corporation	INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS

1998
- 1998-12-22 RU RU2000120162/04A patent/RU2265597C2/ru not_active IP Right Cessation
- 1998-12-22 WO PCT/US1998/026082 patent/WO1999032455A1/en active IP Right Grant
- 1998-12-22 ID IDW20001417A patent/ID26328A/id unknown
- 1998-12-22 NZ NZ505845A patent/NZ505845A/en not_active IP Right Cessation
- 1998-12-22 UA UA2000074353A patent/UA67763C2/uk unknown
- 1998-12-22 BR BR9814361-1A patent/BR9814361A/pt not_active IP Right Cessation
- 1998-12-22 TR TR2001/00918T patent/TR200100918T2/xx unknown
- 1998-12-22 DK DK98963810T patent/DK1056725T3/da active
- 1998-12-22 EP EP98963810A patent/EP1056725B1/en not_active Expired - Lifetime
- 1998-12-22 ES ES98963810T patent/ES2155045T3/es not_active Expired - Lifetime
- 1998-12-22 IL IL13677398A patent/IL136773A0/xx active IP Right Grant
- 1998-12-22 DE DE1056725T patent/DE1056725T1/de active Pending
- 1998-12-22 TR TR2000/02617T patent/TR200002617T2/xx unknown
- 1998-12-22 KR KR1020007007014A patent/KR100622138B1/ko not_active IP Right Cessation
- 1998-12-22 HU HU0004426A patent/HUP0004426A3/hu unknown
- 1998-12-22 AU AU19055/99A patent/AU765412B2/en not_active Ceased
- 1998-12-22 PL PL98341356A patent/PL341356A1/xx not_active Application Discontinuation
- 1998-12-22 SK SK962-2000A patent/SK285371B6/sk not_active IP Right Cessation
- 1998-12-22 TR TR2001/00917T patent/TR200100917T2/xx unknown
- 1998-12-22 AT AT98963810T patent/ATE328873T1/de active
- 1998-12-22 JP JP2000525392A patent/JP4395823B2/ja not_active Expired - Fee Related
- 1998-12-22 CZ CZ20002349A patent/CZ299836B6/cs not_active IP Right Cessation
- 1998-12-22 PT PT98963810T patent/PT1056725E/pt unknown
- 1998-12-22 CA CA2315713A patent/CA2315713C/en not_active Expired - Fee Related
- 1998-12-22 CN CN98812504A patent/CN1117081C/zh not_active Expired - Fee Related
- 1998-12-22 DE DE69834842T patent/DE69834842T2/de not_active Expired - Lifetime
2000
- 2000-06-14 IL IL136773A patent/IL136773A/en not_active IP Right Cessation
- 2000-06-21 NO NO20003231A patent/NO319209B1/no not_active IP Right Cessation
- 2000-06-22 CU CU152A patent/CU23127A3/es not_active IP Right Cessation
- 2000-07-12 BG BG104598A patent/BG65207B1/bg unknown
2001
- 2001-01-30 HK HK01100659A patent/HK1029989A1/xx not_active IP Right Cessation
- 2001-03-30 GR GR20010300010T patent/GR20010300010T1/el unknown
2006
- 2006-09-06 CY CY20061101275T patent/CY1105395T1/el unknown

Also Published As

Publication number	Publication date
ID26328A (id)	2000-12-14
BR9814361A (pt)	2001-11-27
DE1056725T1 (de)	2001-06-07
BG65207B1 (bg)	2007-07-31
CU23127A3 (es)	2006-04-18
ES2155045T3 (es)	2007-02-01
IL136773A (en)	2006-10-31
CN1283192A (zh)	2001-02-07
HUP0004426A2 (hu)	2001-05-28
CA2315713A1 (en)	1999-07-01
DE69834842T2 (de)	2007-05-10
EP1056725B1 (en)	2006-06-07
WO1999032455A1 (en)	1999-07-01
PT1056725E (pt)	2006-09-29
HUP0004426A3 (en)	2001-07-30
HK1029989A1 (en)	2001-04-20
GR20010300010T1 (en)	2001-03-30
CA2315713C (en)	2011-02-01
RU2265597C2 (ru)	2005-12-10
DE69834842D1 (de)	2006-07-20
ATE328873T1 (de)	2006-06-15
BG104598A (en)	2001-02-28
JP4395823B2 (ja)	2010-01-13
CN1117081C (zh)	2003-08-06
SK9622000A3 (en)	2001-01-18
ES2155045T1 (es)	2001-05-01
NZ505845A (en)	2003-10-31
CY1105395T1 (el)	2010-07-28
EP1056725A1 (en)	2000-12-06
TR200100917T2 (tr)	2001-07-23
SK285371B6 (sk)	2006-12-07
AU1905599A (en)	1999-07-12
EP1056725A4 (en)	2001-02-07
PL341356A1 (en)	2001-04-09
TR200100918T2 (tr)	2001-06-21
IL136773A0 (en)	2001-06-14
CZ299836B6 (cs)	2008-12-10
JP2001526269A (ja)	2001-12-18
TR200002617T2 (tr)	2000-11-21
UA67763C2 (uk)	2004-07-15
NO20003231L (no)	2000-08-22
CZ20002349A3 (en)	2001-05-16
AU765412B2 (en)	2003-09-18
KR100622138B1 (ko)	2006-09-13
KR20010033513A (ko)	2001-04-25
NO20003231D0 (no)	2000-06-21
NO319209B1 (no)	2005-06-27

Publication	Publication Date	Title
DK1056725T3 (da)	2006-10-02	Inhibering af raf-kinase ved hjælp af aryl- og heteroaryl-substituerede heterocykliske urinstoffer
DK1047418T3 (da)	2005-11-21	Inhibering af raf-kinase ved hjælp af substituerede heterocykliske urinstoffer
DK0986382T3 (da)	2008-10-20	RAF-kinasehæmmere
DK1070056T3 (da)	2004-11-08	Phthalazinon-PDE III/IV-inhibitorer
EA200000098A1 (ru)	2000-08-28	4-АМИНОПИРРОЛ(3,2-d)ПИРИМИДИНЫ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА НЕЙРОПЕПТИДА Y
ATE417828T1 (de)	2009-01-15	Heterocyclische inhibitoren von p38
DK0901374T3 (da)	2004-04-05	Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
DE60210751D1 (de)	2006-05-24	Sterisch gehinderte n-(hydroxy-alkoxy)-substituierte amine und damit stabilisierte zusammensetzungen
ATE245642T1 (de)	2003-08-15	Benzamide mit tetrahydrofuranyloxy-substituenten als inhibitoren der phosphodiesterase 4
ATE281439T1 (de)	2004-11-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
EA200100051A1 (ru)	2001-08-27	Ингибиторы fkbp
DE60228134D1 (de)	2008-09-18	Substituierte hydrazone als hemmer von cyclooxygenase-2